f Brain Targeted Drug Delivery System for Microglial Diseases: Recent Developments in Neuroinflammation and Neurodegeneration

References

1. WongH.L. WuX.Y. BendayanR. Nanotechnological advances for the delivery of CNS therapeutics.Adv. Drug Deliv. Rev.201264768670010.1016/j.addr.2011.10.00722100125
   [Google Scholar]
2. YuY. HeS. KongL. Brain-targeted multifunctional micelles delivering Oridonin and Phillyrin for synergistic therapy of Alzheimer’s disease.J. Drug Deliv. Sci. Technol.20238710479410.1016/j.jddst.2023.104794
   [Google Scholar]
3. BashyalS. ThapaC. LeeS. Recent progresses in exosome-based systems for targeted drug delivery to the brain.J. Control. Release202234872374410.1016/j.jconrel.2022.06.01135718214
   [Google Scholar]
4. ChenJ. ShanS. XiaB. ZhangL. LiangX.J. Brain‐targeted exosomes‐based drug delivery system to overcome the treatment bottleneck of brainstem glioma.Advanced Functional Materials20233333230237810.1002/adfm.202302378
   [Google Scholar]
5. KuhadA. BhandariR. PaliwalJ.K. Enhanced bioavailability and higher uptake of brain-targeted surface engineered delivery system of naringenin developed as a therapeutic for autism spectrum disorder.Curr. Drug Deliv.202320215818210.2174/156720181966622030310150635240971
   [Google Scholar]
6. CerqueiraS.R. OliveiraJ.M. SilvaN.A. Microglia response and in vivo therapeutic potential of methylprednisolone-loaded dendrimer nanoparticles in spinal cord injury.Small20139573874910.1002/smll.20120188823161735
   [Google Scholar]
7. LiuJ. YangB. KeJ. LiW. SuenW.C. Antibody-based drugs and approaches against amyloid-β species for Alzheimer’s disease immunotherapy.Drugs Aging2016331068569710.1007/s40266‑016‑0406‑x27699633
   [Google Scholar]
8. MitraS. GeraR. SundheimerJ. The microglial challenge to encapsulated cell mediated drug delivery in brain tissue.Alzheimers Dement.202319S7e06823710.1002/alz.068237
   [Google Scholar]
9. SinghM. MazumderB. Recent advancements in nanodiamond mediated brain targeted drug delivery and bioimaging of brain ailments: A holistic review.Pharm. Nanotechnol.2022101425510.2174/221173851066621122211193834951376
   [Google Scholar]
10. HuangD. WangQ. CaoY. Multiscale NIR-II imaging-guided brain-targeted drug delivery using engineered cell membrane nanoformulation for alzheimer’s disease therapy.ACS Nano20231755033504610.1021/acsnano.2c1284036867454
    [Google Scholar]
11. YangF. ZhaoD. ChengM. mTOR-mediated immunometabolic reprogramming nanomodulators enable sensitive switching of energy deprivationinduced microglial polarization for Alzheimer’s disease management.ACS Nano20231716157241574110.1021/acsnano.3c0323237565731
    [Google Scholar]
12. VeselovV.V. EroshchenkoN.N. TrukhanV.M. ZvyaginA.V. NosyrevA.E. Using liposomal and intranasal drugs and pioglitazone for the treatment and prevention of alzheimer’s disease (Review).Pharm. Chem. J.20235711910.1007/s11094‑023‑02845‑w
    [Google Scholar]
13. RezaieJ. AkbariA. RahbarghaziR. Inhibition of extracellular vesicle biogenesis in tumor cells: A possible way to reduce tumorigenesis.Cell Biochem. Funct.202240324826210.1002/cbf.369535285964
    [Google Scholar]
14. SunY. ZabihiM. LiQ. Drug permeability: From the blood–brain barrier to the peripheral nerve barriers.Adv. Ther.202364220015010.1002/adtp.20220015037649593
    [Google Scholar]
15. RassuG. SorrentiM. CatenacciL. Conjugation, prodrug, and co-administration strategies in support of nanotechnologies to improve the therapeutic efficacy of phytochemicals in the central nervous system.Pharmaceutics2023156157810.3390/pharmaceutics1506157837376027
    [Google Scholar]
16. MalongL. NapoliI. CasalG. Characterization of the structure and control of the blood-nerve barrier identifies avenues for therapeutic delivery.Dev. Cell2023583174191.e810.1016/j.devcel.2023.01.00236706755
    [Google Scholar]